Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Uncovering PD-L1 among immune cell predictive biomarkers and actionable genetic alterations in anal squamous-cell carcinomas in the era of immunotherapy.

ESMO open - 1 Jun 2025

Sharma G, Baca Y, Shields A F, Prakash A, Weinberg B A, Saeed A, Goel S, Abdalla A, Oberley M, Xiu J, Hwang J, Antonarakis E S, Chiu V K, Lou E

Abstract excerpt

BACKGROUND: Anal squamous-cell carcinoma (ASCC) is a rare cancer. Immune checkpoint inhibitors (ICIs) are used as a second-line treatment. We aimed to analyze the genomic and transcriptomic profiles of ASCC to predict ICI efficacy. MATERIALS AND METHODS: Next-generation sequencing (NGS) of DNA and RNA was carried out. Programmed death- ligand 1 (PD-L1) expression was tested by immunohistochemistry (IHC) as high...

Read the complete abstract on PubMed

Topics

Humans
B7-H1 Antigen
Anus Neoplasms
Male
Female
Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Carcinoma, Squamous Cell

Middle Aged

Immunotherapy

Aged

Immune Checkpoint Inhibitors

Tumor Microenvironment

Mutation

Adult

Microsatellite Instability

Source

Open in PubMed Open full text

Identifiers

PMID: 40499464
DOI: 10.1016/j.esmoop.2025.105315
PMCID: PMC12182785

Genes

CASP8
PIK3CA
CD274
CD80
CD86
CTLA4
IDO1
IFNG
LAG3
PDCD1
PDCD1LG2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 19 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Uncovering PD-L1 among immune cell predictive biomarkers and actionable genetic alterations in anal squamous-cell carcinomas in the era of immunotherapy.PMID 40499464Read ↗

Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy.Semantic proximity Read ↗

Large-Scale Meta-Analysis of Potential Biomarkers for Treatment Response to Anti-PD-1/PD-L1 Immune Checkpoint InhibitorsSemantic proximity Read ↗

Advances and prospects of biomarkers for immune checkpoint inhibitorsSemantic proximity Read ↗

Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor ImmunotherapySemantic proximity Read ↗

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on BiomarkersSemantic proximity Read ↗

Transcriptomic Immune-related Signature Predictive of Chemoradiotherapy Response in Anal Squamous Cell CarcinomaSemantic proximity Read ↗

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on BiomarkersSemantic proximity Read ↗

Transcriptomic Immune-related Signature Predictive of Chemoradiotherapy Response in Anal Squamous Cell CarcinomaSemantic proximity Read ↗

Immune Checkpoint Gene Expression Profiling Identifies Programmed Cell Death Ligand-1 Centered Immunologic Subtypes of Oral and Squamous Cell Carcinoma With Favorable SurvivalSemantic proximity Read ↗

Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.Semantic proximity Read ↗

A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.Semantic proximity Read ↗

PD-L1 expression and tumor mutational burden are independent biomarkers in most cancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.